IP Library › Granted Patent US 12,599,617
Granted Patent B2
US 12,599,617 · App. 18/049,966 · Granted Apr 14, 2026

Methods of treating head and neck cancers with hemp extract

Inventors: Alexandra M. Capano (Philadelphia, PA); Pradeep Singh Tanwar (Fletcher, AU); Alex Nance (Georgetown, KY)
Assignee: Dove Innovation Pty Limited
A61K31/658A61K9/0053A61K31/282A61K31/337A61K31/513A61K31/519A61K31/704A61K33/243A61K36/3482A61K39/3955A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,617
App. No.
18/049,966
Granted
Apr 14, 2026
Kind
B2
Abstract

A method for treating a head or neck cancer comprising: administering to a patient an effective amount of a composition comprising a cannabis extract comprising cannabidiol (CBD), wherein the composition is preferably administered as a mucosal formulation.

Claims (17)

1 . A method for treating head and neck cancer comprising administering to a patient an effective amount of a composition comprising a cannabis extract (CE) comprising between 50% and 99.9% cannabidiol (CBD) by weight and wherein the composition has a pH of between 2 and 5.5.

2 . The method of claim 1 wherein the CE is selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), and a CBD isolate.

3 . The method of claim 1 wherein the CE is administered via an oral form, oral mucosal form, intravaginal form, nasal mucosal form, rectal form, injectable form, or combinations thereof.

4 . The method of claim 1 wherein the effective amount of the cannabis extract comprising CBD comprises between 10 mg and 4,250 mg of CBD per day.

5 . The method of claim 1 wherein administration of the CE is a dose given at least once a day, at least twice a day, or at least three times a day.

6 . The method of claim 1 wherein the head and neck cancer is a grade 1, grade 2, or grade 3 cancer.

7 . The method of claim 1 wherein the head and neck cancer is a chemoresistant head and neck cancer.

8 . The method of claim 1 wherein the CE further comprises CBDA at a concentration of between 0.1% and 10%.

9 . The method of claim 1 wherein the CE is a BSHE or FSHE and wherein each of the BSHE or FSHE comprises 50% to 99.9% by weight of CBD and at least one other cannabinoid at a concentration of 0.1% to 10% by weight wherein the at least one other cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

10 . The method of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the total weight of the composition.

11 . The method of claim 1 wherein the composition comprises an oil or a fat as a carrier.

12 . The method of claim 1 wherein the effective amount of the composition is an amount sufficient to reach an effective therapeutic level of CBD as measured through systemic plasma levels.

13 . A method of treatment of head and neck cancer comprising administering to a patient an effective amount of a chemotherapeutic agent and coadministering an effective amount of an oral mucosal composition comprising a cannabis extract (CE) comprising between 50% and 99.9% cannabidiol (CBD) by weight and wherein the composition has a pH of between 2 and 5.5.

14 . The method of claim 13 wherein the chemotherapeutic agent and the CE are administered as one composition or as two different compositions.

15 . The method of claim 13 wherein the chemotherapeutic agent is selected from the group consisting of: paclitaxel, carboplatin, doxorubicin, cisplatin, docetaxel, fluorouracil, methotrexate, cetuximab, and combinations thereof.

16 . The method of claim 13 wherein the effective amount of the composition is sufficient to reach an effective therapeutic level as measured through systemic plasma levels of CBD.

17 . A method for treating a head and neck cancer comprising administering to a patient an effective amount of a composition, said composition comprising a carrier and a cannabis extract (CE) comprising cannabidiol (CBD), said composition comprising between 50% and 99.9% CBD by weight, and wherein the composition has a pH of between 2 and 5.5.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2025
From: ECOFIBRE USA, INC.
To: DOVE INNOVATION PTY LIMITED
Reel/Frame 072141/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: ECOFIBRE LIMITED
To: ECOFIBRE USA INC.
Reel/Frame 064464/0611 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2023
From: CAPANO, ALEXANDRA M.
To: ECOFIBRE LIMITED
Reel/Frame 062984/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2023
From: NANCE, ALEX
To: ECOFIBRE LIMITED
Reel/Frame 062984/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2023
From: TANWAR, PRADEEP SINGH
To: THE UNIVERSITY OF NEWCASTLE
Reel/Frame 062984/0730 →
Continuity (3)
Provisional Application 63263019 · Oct 26, 2021
Provisional Application 63263026 · Oct 26, 2021
Related Publication 20230130065A1 · Apr 27, 2023
References Cited (103)
US 10098867B2 · Javid et al. · 2018 [cited by applicant]
US 11123308B2 · Yu et al. · 2021 [cited by applicant]
US 20100273895A1 · Stinchcomb et al. · 2010 [cited by applicant]
US 20110086113A1 · Velasco Diez et al. · 2011 [cited by applicant]
US 20150086653A1 · Parolaro et al. · 2015 [cited by applicant]
US 20160136128A1 · Javid et al. · 2016 [cited by applicant]
US 20190282513A1 · Yerike · 2019 [cited by applicant]
US 20200253919A1 · Raz et al. · 2020 [cited by applicant]
US 20200408740A1 · Ballan et al. · 2020 [cited by applicant]
US 20210052512A1 · Guy et al. · 2021 [cited by applicant]
US 20210068444A1 · Alarcon et al. · 2021 [cited by applicant]
US 20210069608A1 · Galyuk · 2021 [cited by applicant]
US 20210085638A1 · Hospodor · 2021 [cited by applicant]
US 20210128521A1 · Palaio · 2021 [cited by applicant]
US 20210145764A1 · Lephart · 2021 [cited by applicant]
US 20220000774A1 · Dely · 2022 [cited by applicant]
US 20220054429A1 · Nathan et al. · 2022 [cited by applicant]
US 20220062224A1 · Gubler et al. · 2022 [cited by applicant]
US 20220193164A1 · White · 2022 [cited by applicant]
US 20220202765A1 · Altman et al. · 2022 [cited by applicant]
US 20220248619A1 · Kleidon · 2022 [cited by applicant]
US 20220253919A1 · Denner · 2022 [cited by applicant]
US 20220331287A1 · Morgan et al. · 2022 [cited by applicant]
US 20230015268A1 · Altman et al. · 2023 [cited by applicant]
US 20230127098A1 · Capano et al. · 2023 [cited by applicant]
US 20230132189A1 · Capano et al. · 2023 [cited by applicant]
US 20230248747A1 · Altman et al. · 2023 [cited by applicant]
US 20230355645A1 · Storch et al. · 2023 [cited by applicant]
CN 108433880A · 2018 [cited by applicant]
CN 110063953A · 2019 [cited by applicant]
EP 3368024A1 · 2018 [cited by applicant]
EP 3449992A1 · 2019 [cited by applicant]
EP 3544598A1 · 2019 [cited by applicant]
EP 3915550A1 · 2021 [cited by applicant]
EP 3937914A1 · 2022 [cited by applicant]
GB 2516335A · 2015 [cited by applicant]
RU 2745687C1 · 2021 [cited by applicant]
WO WO2013165251A1 · 2013 [cited by applicant]
WO WO2014057067A1 · 2014 [cited by applicant]
WO WO2016187679A1 · 2016 [cited by applicant]
WO WO2017072773A1 · 2017 [cited by applicant]
WO WO2018167038A1 · 2018 [cited by applicant]
WO WO2019003163A2 · 2019 [cited by applicant]
WO WO2019034113A1 · 2019 [cited by applicant]
WO WO2019106652A1 · 2019 [cited by applicant]
WO WO2019145552A1 · 2019 [cited by applicant]
WO WO2019195943A1 · 2019 [cited by applicant]
WO WO2019222459A1 · 2019 [cited by applicant]
WO WO2020036655A9 · 2020 [cited by applicant]
WO WO2020165878A1 · 2020 [cited by applicant]
WO WO2020163775A1 · 2020 [cited by examiner]
WO WO2020183455A1 · 2020 [cited by applicant]
WO WO2020194237A1 · 2020 [cited by applicant]
WO WO2020209902A1 · 2020 [cited by applicant]
WO WO2021011790A1 · 2021 [cited by applicant]
WO WO2021016718A1 · 2021 [cited by applicant]
WO WO2021028646A1 · 2021 [cited by applicant]
WO WO2021099792A1 · 2021 [cited by applicant]
WO WO2021130728A1 · 2021 [cited by applicant]
WO WO2021158251A1 · 2021 [cited by applicant]
WO WO2021235977A1 · 2021 [cited by applicant]
WO WO2021240510A1 · 2021 [cited by applicant]
WO WO2021245522A1 · 2021 [cited by applicant]
WO WO2022013854A1 · 2022 [cited by applicant]
WO WO2022016160A1 · 2022 [cited by applicant]
WO WO2022018708A1 · 2022 [cited by applicant]
WO WO2022105952A1 · 2022 [cited by applicant]
WO WO2022118303A1 · 2022 [cited by applicant]
WO WO2022144878A1 · 2022 [cited by applicant]
WO WO2022165349A1 · 2022 [cited by applicant]
WO WO2022165439A1 · 2022 [cited by applicant]
WO WO2022201043A1 · 2022 [cited by applicant]
WO WO2022215071A1 · 2022 [cited by applicant]
WO WO2022225658A1 · 2022 [cited by applicant]
WO WO2023287742A1 · 2023 [cited by applicant]
WO WO2023014818A2 · 2023 [cited by applicant]
WO WO2023062634A1 · 2023 [cited by applicant]
Go et al., “Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma” Scientific Reports, vol. 10, No. 1, art. 20622, Nov. 26, 2020, 1-11 (Year: 2020). [cited by examiner]
Jaidee et al., Kinetics of CBD, Δ9-THC Degradation and Cannabinol Formation in Cannabis Resin at Various Temperature and pH Conditions, Cannabis and Cannabinoid Research, vol. 7, No. 4, Aug. 2022 (available online Jun. … [cited by examiner]
International Search Report issued in International Application No. PCT/US2022/078698 dated Dec. 14, 2022. [cited by applicant]
International Search Report issued in International Application No. PCT/US2022/078691 dated Jan. 30, 2023. [cited by applicant]
International Search Report issued in International Application No. PCT/US2022/078693 dated Jan. 30, 2023. [cited by applicant]
Fonseca, et al., “Cannabinoid-Induced Cell Death in Endometrial Cancer Cells: Involvement of TRPV1 Receptors in Apoptosis”, Journal of Physiology and Biochemistry, vol. 74, No. 2, Feb. 13, 2018, 261-272. [cited by applicant]
Fraguas-Sánchez, et al., “Enhancing Ovarian Cancer Conventional Chemotherapy Through the Combination With Cannabidiol Loaded Microparticles”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 154, Jul. 17, 20… [cited by applicant]
Go, et al., “Cannabidiol Enhances Cytotoxicity of Anti-Cancer Drugs in Human Head and Neck Squamous Cell Carcinoma”, Scientific Reports, vol. 10, No. 1, art. 20622, Nov. 26, 2020, 1-11. [cited by applicant]
Griffiths, et al., “Cannabidiol Suppresses 3-Dimensional Ovarian Cancer Growth and May Enhance Potency of Classic and Epigenetic Therapies”, Gynecologic Oncology, vol. 162, suppl. 1, Abstracts for the 2021 Society of Gy… [cited by applicant]
Kenyon, et al., “Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-Grade Synthetic Cannabidiol”, Anticancer Research, vol. 38, No. 10, Oct. 1, 2018, 5831-5835. [cited by applicant]
Marinelli, et al., “The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer”, International Journal of Molecular Sciences, vol. 21, No. 15, art. 5409, Jul. 29, 2020, 1-22. [cited by applicant]
Rush, et al., “Cannabidiol: Assessing Activity in Ovarian and Endometrial Carcinoma Cell Lines”, Abstracts for the 2021 Society of Gynecologic Oncology 52nd Annual Meeting on Women's Cancer, Featured Posters 188-Poster … [cited by applicant]
International Search Report issued in International Application No. PCT/US2022/078701 dated Feb. 15, 2023. [cited by applicant]
Armour, et al., “Self-Management Strategies Amongst Australian Women With Endometriosis: A National Online Survey”, BMC Complementary and Alternative Medicine, vol. 19, No. 1, art. 17, Jan. 15, 2019, 1-8. [cited by applicant]
Escudero-Lara, et al., “Disease-Modifying Effects of Natural A3-Tetrahydrocannabinol in Endometriosis-Associated Pain”, eLife, vol. 9, art. e50356, Jan. 14, 2020, https://elifesciences.org/articles/50356. [cited by applicant]
Jin, et al., “Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots”, Frontiers in Plant Science, vol. 12, ar… [cited by applicant]
Lazarjani, et al., “Processing and Extraction Methods of Medicinal Cannabis: A Narrative Review”, Journal of Cannabis Research, vol. 3, art. 32, Jul. 19, 2021, 1-15. [cited by applicant]
Marinotti, et al., “Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science”, Journal of Dietary Supplements, vol. 17, No. 5, Jun. 16, 2020, 517-526. [cited by applicant]
Ökten, et al., “Cannabidiol as a Potential Novel Treatment for Endometriosis by Its Anti-Inflammatory and Anti-Oxidative Effects in an Experimental Rat Model”, Human Reproduction, vol. 37, issue supp. 1, Jun. 30, 2022, … [cited by applicant]
Rais, et al., “Phytochemicals in the Treatment of Ovarian Cancer”, Frontiers in Bioscience-Elite, vol. 9, No. 1, Jan. 1, 2017, 67-75. [cited by applicant]
Sumanasekera, et al., “Hemp Extract With Specific Anti-Cancer Properties Against Ovarian Cancer”, The FASEB Journal Special Issue: Experimental Biology 2021 Meeting Abstracts, vol. 35, No. S1, May 14, 2021, https://doi.… [cited by applicant]
Midatech Pharma US Inc., Soltamox® Product Label, Revised Apr. 2019. [cited by applicant]
Olivas-Aguirre, et al., “Tamoxifen Sensitizes Acute Lymphoblastic Leukemia Cells to Cannabidiol by Targeting Cyclophilin-D and Altering Mitochondrial Ca [cited by applicant]
Hazekamp, et al., “Preparative Isolation of Cannabinoids from Cannabis sativa by Centrifugal Partition Chromatography”, Journal of Liquid Chromatography & Related Technologies, vol. 27, No. 15, 2004, 2421-2439. [cited by applicant]
Van Weelden, et al., “Anti-Estrogen Treatment in Endometrial Cancer: A Systematic Review”, Frontiers in Oncology, vol. 9, art. 359, May 7, 2019, 1-12. [cited by applicant]
Boretto, et al., “Patient-Derived Organoids From Endometrial Disease Capture Clinical Heterogeneity and Are Amenable to Drug Screening”, Nature Cell Biology, vol. 21, Aug. 1, 2019, 1041-1051. [cited by applicant]